Company Overview Ipsen Limited is the UK subsidiary of Ipsen, a European pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,200. Ipsen Limited's Endocrinology and Oncology Business Unit is responsible for a portfolio of products including Decapeptyl® (triptorelin), Increlex® (mecasermin), NutropinAq® (somatropin), Somatuline® (lanreotide) Autogel®, and Somatuline® (lanreotide) LA. The Neurology Business Unit is responsible for Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex). Ipsen specialises in treatments for the following diseases: - Acronegaly
- Neuroendocrine Tumours
- Dystonia
- Belpharospasm
- Cervical dystonia
- Hemifacial Spasm
- Endometriosis
| 
